Owlet’s stock has seen its consensus analyst price target rise from $13.20 to $14.83, which underscores renewed optimism about its future performance. This positive shift is largely driven by growing confidence in Owlet’s revenue growth potential and a recent successful stock offering that has strengthened its financial position. Stay tuned to learn how you can follow these evolving perspectives and stay informed about the latest developments shaping the narrative for Owlet’s stock.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Owlet.

Analyst commentary on Owlet has recently centered on its improved liquidity position, regulatory differentiation, and ongoing growth prospects. Below, we outline the key themes emerging from the latest street research.

???? Bullish Takeaways

Northland analyst Owen Rickert raised the firm's price target on Owlet to $15.50 from $12 after what was described as "a solid quarter." The analyst noted that the recent stock offering meaningfully increased Owlet's liquidity and provided the company with ample resources to invest in research and development through 2026.

Northland also highlighted Owlet's unique competitive advantages following an FDA communication warning about the risks of unauthorized infant monitors. Owlet's Dream Sock is identified as the first and only over-the-counter FDA approved infant monitoring device, which reinforces the company's regulatory moat in the market.

???? Bearish Takeaways

While Northland maintains an Outperform rating throughout their updated coverage, their commentary notes that the FDA's risk alert places a strong emphasis on regulatory compliance. While this is currently an advantage for Owlet, it signals a near-term industry risk for companies lacking similar approvals.

The analyst coverage to date does not specifically cite reservations related to valuation or downside risks in their public statements and instead focuses more on Owlet's strengths than on potential headwinds.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Owlet raised its full-year 2025 earnings guidance and is now forecasting revenue between $103 million and $106 million, representing 32 percent to 36 percent year-over-year growth.

The company completed a $30 million follow-on equity offering, which further improved its balance sheet and provided capital reserves for future initiatives.

Dream Sock received regulatory approval from India's Central Drugs Standard Control Organization, allowing Owlet to expand into the Indian market with several product launches expected in early 2026.

Owlet announced a partnership with Rhapsody. This partnership is intended to integrate health data from its FDA-cleared pulse oximeter directly into provider electronic health records, streamlining how clinicians access patient information.

Consensus Analyst Price Target has increased from $13.20 to $14.83, reflecting higher expectations for the stock’s future value.

Discount Rate has risen slightly from 7.81% to 7.87%, suggesting a marginally higher perceived risk or cost of capital.

Revenue Growth estimate has improved from 23.0% to 25.8%, indicating analysts expect stronger topline expansion ahead.

Net Profit Margin forecast has advanced significantly from 2.65% to 10.70%, pointing to expectations of much improved profitability.

Future P/E (Price-to-Earnings) ratio has fallen substantially from 74.6x to 28.9x. This implies a more favorable valuation as earnings forecasts rise.

A Narrative is the story behind a company’s numbers, connecting forecasts, financials, and fair value into a single, easy-to-read perspective. Narratives on Simply Wall St help millions of investors quickly grasp why a stock may be undervalued or overhyped, compare price to fair value, and spot opportunities. They update automatically with the latest news or earnings so you always see the freshest insights on the Community page.

Check out the original Narrative for Owlet to stay ahead on:

How regulatory clearances and expanding product offerings drive Owlet’s long-term revenue growth and strengthen its market leadership.

Why recurring subscription revenue, integration with healthcare providers, and predictive analytics are building a foundation for durable, higher-margin earnings.

What risks such as healthcare channel adoption, tariff exposure, and product concentration could challenge margin expansion and sustained growth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include OWLT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com